A detailed history of Headinvest, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Headinvest, LLC holds 2,458 shares of VRTX stock, worth $1.16 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
2,458
Previous 1,727 42.33%
Holding current value
$1.16 Million
Previous $721,000 59.78%
% of portfolio
0.23%
Previous 0.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $287,144 - $354,922
731 Added 42.33%
2,458 $1.15 Million
Q1 2024

Aug 14, 2024

BUY
$407.69 - $446.08 $276,821 - $302,888
679 Added 64.79%
1,727 $721,000
Q4 2023

Feb 12, 2024

SELL
$343.0 - $410.68 $8,575 - $10,267
-25 Reduced 2.33%
1,048 $426,000
Q2 2023

Aug 23, 2023

SELL
$314.42 - $351.91 $7,231 - $8,093
-23 Reduced 2.1%
1,073 $377,000
Q1 2023

May 17, 2023

SELL
$283.23 - $323.1 $14,161 - $16,155
-50 Reduced 4.36%
1,096 $345,000
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $21,717 - $24,432
-76 Reduced 6.22%
1,146 $330,000
Q3 2022

Dec 28, 2022

BUY
$273.83 - $305.53 $2,738 - $3,055
10 Added 0.83%
1,222 $354,000
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $3,764 - $4,436
-17 Reduced 1.38%
1,212 $316,000
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $10,620 - $13,407
60 Added 5.13%
1,229 $270,000
Q3 2021

Nov 16, 2021

SELL
$181.39 - $202.99 $4,897 - $5,480
-27 Reduced 2.26%
1,169 $212,000
Q2 2021

Aug 30, 2021

BUY
$187.49 - $221.1 $7,687 - $9,065
41 Added 3.55%
1,196 $241,000
Q1 2021

May 13, 2021

BUY
$207.02 - $241.31 $239,108 - $278,713
1,155 New
1,155 $248,000
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $213,841 - $285,200
-1,033 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $213,841 - $285,200
1,033 New
1,033 $244,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Headinvest, LLC Portfolio

Follow Headinvest, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headinvest, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headinvest, LLC with notifications on news.